Clinical trial
Gemcitabine and Oxaliplatin (GEMOX) in First Line Metastatic or Recurrent…
NCT00436800 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00436800 |
|---|---|
| Title | Gemcitabine and Oxaliplatin (GEMOX) in First Line Metastatic or Recurrent Nasopharyngeal Carcinoma |
| Official title | Gemcitabine and Oxaliplatin in First Line Metastatic or Recurrent Nasopharyngeal Carcinoma (NPC) |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Nasopharyngeal Neoplasms |
| Intervention type | Drug |
| Interventions | Gemcitabine, Oxaliplatin |
| Enrollment | 41 |
| Start date | Mar 1, 2005 |
| Primary completion | Oct 1, 2008 |
| Completion | Oct 1, 2008 |
| First posted | Feb 19, 2007 |
| Last update posted | Sep 18, 2009 |
| Countries | Hong Kong |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: